Pediatric Endocrinology Group, Girona Biomedical Research Institute (IDIBGI), Dr. Trueta University Hospital, Girona 17007, Spain.
Department of Gynecology, Dr. Trueta University Hospital, Girona 17007, Spain.
J Clin Endocrinol Metab. 2017 Jul 1;102(7):2584-2594. doi: 10.1210/jc.2017-00089.
Human placenta exhibits a specific microRNA (miRNA) expression pattern. Some of these miRNAs are dysregulated in pregnancy disorders such as preeclampsia and intrauterine growth restriction and are potential biomarkers for these pathologies.
To study the placental miRNA profile in pregnant women with pregestational overweight/obesity (preOB) or gestational obesity (gestOB) and explore the associations between placental miRNAs dysregulated in maternal obesity and prenatal and postnatal growth.
TaqMan Low Density Arrays and real-time polymerase chain reaction were used to profile the placental miRNAs in 70 pregnant women (20 preOB, 25 gestOB, and 25 control). Placentas and newborns were weighed at delivery, and infants were weighed at 1, 4, and 12 months of age.
Eight miRNAs were decreased in placentas from preOB or gestOB (miR-100, miR-1269, miR-1285, miR-181, miR-185, miR-214, miR-296, and miR-487) (all P < 0.05). Among them, miR-100, miR-1285, miR-296, and miR-487 were associated with maternal metabolic parameters (all P < 0.05) and were predictors of lower birth weight (all P < 0.05; R2 > 30%) and increased postnatal weight gain (all P < 0.05; R2 > 20%). In silico analysis showed that these miRNAs were related to cell proliferation and insulin signaling pathways. miR-296 was also present in plasma samples and associated with placental expression and prenatal and postnatal growth parameters (all P < 0.05).
We identified a specific placental miRNA profile in maternal obesity. Placental miRNAs dysregulated in maternal obesity may be involved in mediation of growth-promoting effects of maternal obesity on offspring and could be used as early markers of prenatal and postnatal growth.
人类胎盘表现出特定的 microRNA(miRNA)表达模式。其中一些 miRNA 在子痫前期和宫内生长受限等妊娠疾病中失调,是这些病理的潜在生物标志物。
研究患有孕前超重/肥胖(preOB)或妊娠肥胖(gestOB)的孕妇的胎盘 miRNA 谱,并探讨母体肥胖中失调的胎盘 miRNA 与产前和产后生长之间的关系。
使用 TaqMan 低密度阵列和实时聚合酶链反应对 70 名孕妇(20 名 preOB、25 名 gestOB 和 25 名对照组)的胎盘 miRNA 进行分析。分娩时称量胎盘和新生儿的体重,婴儿在 1、4 和 12 个月时称重。
8 种 miRNA 在 preOB 或 gestOB 的胎盘组织中减少(miR-100、miR-1269、miR-1285、miR-181、miR-185、miR-214、miR-296 和 miR-487)(均 P < 0.05)。其中,miR-100、miR-1285、miR-296 和 miR-487 与母体代谢参数相关(均 P < 0.05),是出生体重较低(均 P < 0.05;R2 > 30%)和产后体重增加增加(均 P < 0.05;R2 > 20%)的预测因子。计算机分析显示,这些 miRNA 与细胞增殖和胰岛素信号通路有关。miR-296 也存在于血浆样本中,与胎盘表达以及产前和产后生长参数相关(均 P < 0.05)。
我们在母体肥胖中确定了一种特定的胎盘 miRNA 谱。母体肥胖中失调的胎盘 miRNA 可能参与介导母体肥胖对后代的生长促进作用,并可作为产前和产后生长的早期标志物。